RU 24969 |
Catalog No.GC37569
One-Click Copy Product Info
|
RU 24969 is a widely used nonselective 5-HT1B/1A agonist with a Ki value of 0.38nM for the 5-HT1B receptor and 2.5nM for the 5-HT1A receptor, but with lower affinity for other receptor sites in the brain.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 66611-26-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
RU 24969 is a widely used nonselective 5-HT1B/1A agonist with a Ki value of 0.38nM for the 5-HT1B receptor and 2.5nM for the 5-HT1A receptor, but with lower affinity for other receptor sites in the brain[1]. RU 24969 induces robust hyperlocomotor activity, characterized by increased forward locomotion and a concomitant reduction in fluid consumption[1].
In vitro, 10μM RU-24969 attenuated 21mM K⁺-induced [³H]-5-HT release in cultured rat frontal cortex slices, reducing it by approximately 30%[2].
In vivo, subcutaneous administration of RU 24969 at doses of 0.3, 1, and 3mg/kg produced a dose-dependent reduction in water intake in male SD rats within a 30-45min observation period. In addition, subcutaneous administration of RU 24969 (3mg/kg) significantly increased total forward locomotion within 15-45min after dosing[1]. Administration of RU-24969 at 10mg/kg by intraperitoneal injection decreased extracellular 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA) in rats[2].
References:
[1] Aronsen D, Webster J, Schenk S. RU 24969-produced adipsia and hyperlocomotion: differential role of 5HT 1A and 5HT 1B receptor mechanisms. Pharmacol Biochem Behav. 2014;124:1-4.
[2] Brazell MP, Marsden CA, Nisbet AP, Routledge C. The 5-HT1 receptor agonist RU-24969 decreases 5-hydroxytryptamine (5-HT) release and metabolism in the rat frontal cortex in vitro and in vivo. Br J Pharmacol. 1985;86(1):209-216.
| Animal experiment [1]: | |
Animal models | Male Sprague–Dawley rats |
Preparation Method | Water bottles were removed and 23.75h later, RU 24969 (0-3mg/kg, s.c.) was administered. The water bottles were reintroduced 15min after the RU 24969 injection. Consumption was measured for a 30min period. Fluid consumption was determined by weighing water bottles before and after the test. |
Dosage form | 0.3, 1, 3mg/kg; once; s.c. |
Applications | Administration of 0.3, 1 and 3mg/kg resulted in a dose-dependent reduction in water intake. |
References: | |
| Cas No. | 66611-26-5 | SDF | |
| Canonical SMILES | COC1=CC=C2C(C(C3=CCNCC3)=CN2)=C1 | ||
| Formula | C14H16N2O | M.Wt | 228.29 |
| Solubility | DMSO: ≥ 30 mg/mL (131.41 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.3804 mL | 21.902 mL | 43.8039 mL |
| 5 mM | 876.1 μL | 4.3804 mL | 8.7608 mL |
| 10 mM | 438 μL | 2.1902 mL | 4.3804 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)